Superworth

GRAIL EPS GRAL

Diluted earnings per share by quarter and over the last twelve months, from 2023.

Last 12 months, to Jun 30, 2026
−$9.75
Latest quarter, Q2 FY26
−$2.56
Fiscal year 2025
−$11.18

GRAIL's earnings per share was −$9.75 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$2.56.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$11.18n/a
FY2024−$64.94n/a
FY2023−$47.21n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$2.56n/a−$9.75
Q1 FY26−$2.29n/a−$10.37
Q4 FY25−$2.44n/a−$11.18
Q3 FY25−$2.46n/a−$11.63
Q2 FY25−$3.18n/a−$13.11
Q1 FY25−$3.10n/a−$60.99
Q4 FY24−$2.89n/a−$64.94
Q3 FY24−$3.94n/a−$68.09
Q2 FY24−$51.06n/a−$92.86
Q1 FY24−$7.05n/a−$48.02
Q4 FY23−$6.04n/a−$47.21
Q3 FY23−$28.71n/an/a

Against its peers

Companies in Medical - Diagnostics & Research nearest GRAIL's size, closest first, today.

CompanyEPS, 12 monthsGrowth
GRALGRAIL−$9.75
LNTHLantheus$4.13+10% a year
BLLNBillionToOne$0.65
CAICaris Life Sciences$0.37
VCYTVeracyte$1.40+324% a year
CDNACareDx$2.07+116% a year
BIOBio-Rad Laboratories$8.25−30% a year
RVTYRevvity$2.10−11% a year
MEDPMedpace$17.05+27% a year
LHLabcorp$12.09+33% a year
DGXQuest Diagnostics$9.41+18% a year
Peer median$3.12

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on GRAIL

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.